Yang Zhou

发表

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC.

Fang Yang, Yalei Wen, Xiaoyun Lu, 2022, European journal of medicinal chemistry.

Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.

Xiaoyun Lu, G. Cook, Chen-Yi Cheung, 2021, Bioorganic & medicinal chemistry.

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.

Tao Zhang, Lin-jiang Tong, Xiaoyun Lu, 2022, Journal of medicinal chemistry.

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13

A. Chinnaiyan, J. Tien, Zhen Wang, 2022, Journal of medicinal chemistry.

Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.

Zheng-chao Tu, Zhen Wang, Zhengqiu Li, 2022, Journal of medicinal chemistry.

A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria

Xiaoyun Lu, Zhengqiu Li, Ke Ding, 2022, Nature Communications.

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.

S. Xiang, Xiaoyun Lu, Zheng-chao Tu, 2022, Journal of medicinal chemistry.

1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.

Zheng-chao Tu, Zhen Wang, Ke Ding, 2022, European journal of medicinal chemistry.

Targeting Gatekeeper Mutations for Kinase Drug Discovery.

S. Xiang, Yang Zhou, Fang Yang, 2022, Journal of medicinal chemistry.

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Xiaoyun Lu, Zheng-chao Tu, Ke Ding, 2022, Molecules.

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.

Zheng-chao Tu, Zhang Zhang, L. Qu, 2022, Journal of medicinal chemistry.

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.

Yong Xu, J. Smaill, Donghai Wu, 2015, ACS medicinal chemistry letters.

Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus

Yong Xu, Wenhui Hu, Xin Zhao, 2015 .

1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor γ and promote the browning of white adipose.

Yong Xu, J. Smaill, Donghai Wu, 2015, Bioorganic & medicinal chemistry.

Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

Yong Xu, A. Bullock, L. Yao, 2016, Journal of medicinal chemistry.

Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy.

Xiaoyun Lu, G. Cook, Chen-Yi Cheung, 2022, European journal of medicinal chemistry.

Quinoline Derivatives Kill Mycobacterium tuberculosis by Activating Glutamate Kinase.

Tianyu Zhang, Yaoju Tan, Shouyong Tan, 2019, Cell chemical biology.

Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.

T. Ran, Xiaoyun Lu, Hongming Chen, 2021, Chemical communications.

Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.

S. Xiang, Zheng-chao Tu, Ke Ding, 2022, European journal of medicinal chemistry.

Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies

S. Xiang, Xiaoyun Lu, Ke Ding, 2021, European Journal of Medicinal Chemistry.

The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.

Yan Zhang, Yong Xu, Donghai Wu, 2016, Bioorganic & medicinal chemistry.

Design, Synthesis, and Evaluation of (R)-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor.

Lin-jiang Tong, Hua Xie, Qian Li, 2023, Journal of medicinal chemistry.

New benzimidazole-2-urea derivates as tubulin inhibitors.

Yong Xu, Dexin Kong, Xiaohong Yang, 2014, Bioorganic & medicinal chemistry letters.

jmbReview Role of folP 1 and folP 2 Genes in the Action of Sulfamethoxazole and Trimethoprim Against Mycobacteria

Yong Xu, Tianyu Zhang, Changwei Wang, 2015 .

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

J. Smaill, Yongheng Chen, Xiaoyun Lu, 2022, Journal of medicinal chemistry.

Discovery of new Lenalidomide derivatives as potent and selective GSPT1 degraders.

Yongxing Wang, Zhen Wang, Ke Ding, 2023, European journal of medicinal chemistry.

A small-molecule drug inhibits autophagy gene expression through the central regulator TFEB

Zaizhou Liu, P. Fang, Haizhong Feng, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.

Licheng Zhou, H. Hur, Zhen Wang, 2022, Journal of medicinal chemistry.

Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve

A. Chinnaiyan, Yuzhuo Wang, Y. Qiao, 2023, Journal of medicinal chemistry.

A Novel Photocaged B-RafV600E Inhibitor toward Precise Melanoma Treatment.

Zhen Wang, Ke Ding, Xiaomei Ren, 2022, Bioorganic & medicinal chemistry letters.

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

J. Smaill, A. Patterson, Xiaojuan Chen, 2024, Journal of medicinal chemistry.

Discovery of Pyrido[2,3-d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment.

Yaoliang Sun, Yang Zhou, Shilin Xu, 2024, Journal of medicinal chemistry.

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.

Ke Ding, Zhang Zhang, Zhi-Min Zhang, 2023, Journal of medicinal chemistry.

Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations.

Zhang Zhang, Zhi-Min Zhang, Yang Zhou, 2024, ACS pharmacology & translational science.